Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CHI-554 · 1 trial · 3 indications
| Name | Type | Description |
|---|---|---|
| CHI-554 | DRUG | hemp-derived CBD in MCT oil |
CHI-554 is an investigational small molecule being developed for the treatment of anxiety. It is in Phase 2 clinical development, and a completed trial has studied its effects on fear, anxiety, and panic. The drug is not approved and remains under investigation.
CHI-554 is being developed by Canopy Growth Corporation, traded under the ticker CGC. The company is conducting clinical research on this investigational drug for anxiety, with a Phase 2 trial already completed.
CHI-554 is in Phase 2 clinical development. One Phase 2 trial has been completed, and the drug is still investigational, meaning it has not been approved for any use. The completed trial enrolled 84 participants.
CHI-554 has one completed Phase 2 trial, identified as NCT04577612, titled "A Randomized Controlled Test of the Effects of CHI-554 on Fear." The trial studied conditions including anxiety, fear, and panic, with an enrollment of 84 participants.
No, CHI-554 is not FDA approved. It is an investigational drug in Phase 2 clinical development for anxiety. A Phase 2 trial has been completed, but the drug has not received regulatory approval and remains under study.